Taiichi Saito1, Kazuhiko Sugiyama2, Seiji Hama3, Fumiyuki Yamasaki3, Takeshi Takayasu3, Ryo Nosaka3, Shumpei Onishi3, Yoshihiro Muragaki4, Takakazu Kawamata4, Kaoru Kurisu3. 1. Department of Neurosurgery, Hiroshima University, Graduate School of Biomedical and Health Science, Hiroshima, Japan; Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan. Electronic address: taiichis@gmail.com. 2. Department of Clinical Oncology and Neuro-oncology Program, Hiroshima University Hospital, Hiroshima, Japan. 3. Department of Neurosurgery, Hiroshima University, Graduate School of Biomedical and Health Science, Hiroshima, Japan. 4. Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Abstract
OBJECTIVE: Glioblastoma (GBM) relapses locally or in a disseminated pattern and is highly resistant to chemoradiotherapy. Although dissemination is associated with poor prognosis for patients with GBM, the clinicopathologic factors that promote dissemination have not been elucidated. Glypican-1 (GPC-1) is a heparin sulfate proteoglycan that is attached to the extracytoplasmic surface of the cell membrane and regulates cell motility. The aim of this study was to determine whether GPC-1 expression correlated with GBM dissemination and patient prognosis. METHODS: GPC-1 expression was examined by immunohistochemistry in 53 patients with GBM who received radiotherapy and temozolomide treatment. We assessed the relationship between dissemination and clinicopathologic factors, including GPC-1 expression. We also evaluated the relationship between GPC-1 expression and overall survival (OS) by uni- and multivariate analyses of a range of clinicopathologic factors, including age, Karnofsky Performance Status, extent of resection, and O6-methylguanine-DNA methyltransferase (MGMT) status. RESULTS: Logistic regression analysis revealed that GPC-1 expression correlated with dissemination (P = 0.0116). Log-rank tests revealed that age, Karnofsky Performance Status, extent of resection, MGMT status, dissemination (P = 0.0008) and GPC-1 expression (P = 0.0011) were significantly correlated with OS. Multivariate analysis indicated that age, MGMT status, and GPC-1 expression were significantly correlated with OS. GPC-1 expression had the highest hazard ratio (2.392) among all regressors. CONCLUSIONS: GPC-1 expression significantly correlated with OS in patients with GBM who received radiotherapy and temozolomide treatment. GPC-1 expression can help predict the occurrence of dissemination and shorter OS in patients with GBM.
OBJECTIVE:Glioblastoma (GBM) relapses locally or in a disseminated pattern and is highly resistant to chemoradiotherapy. Although dissemination is associated with poor prognosis for patients with GBM, the clinicopathologic factors that promote dissemination have not been elucidated. Glypican-1 (GPC-1) is a heparin sulfate proteoglycan that is attached to the extracytoplasmic surface of the cell membrane and regulates cell motility. The aim of this study was to determine whether GPC-1 expression correlated with GBM dissemination and patient prognosis. METHODS:GPC-1 expression was examined by immunohistochemistry in 53 patients with GBM who received radiotherapy and temozolomide treatment. We assessed the relationship between dissemination and clinicopathologic factors, including GPC-1 expression. We also evaluated the relationship between GPC-1 expression and overall survival (OS) by uni- and multivariate analyses of a range of clinicopathologic factors, including age, Karnofsky Performance Status, extent of resection, and O6-methylguanine-DNA methyltransferase (MGMT) status. RESULTS: Logistic regression analysis revealed that GPC-1 expression correlated with dissemination (P = 0.0116). Log-rank tests revealed that age, Karnofsky Performance Status, extent of resection, MGMT status, dissemination (P = 0.0008) and GPC-1 expression (P = 0.0011) were significantly correlated with OS. Multivariate analysis indicated that age, MGMT status, and GPC-1 expression were significantly correlated with OS. GPC-1 expression had the highest hazard ratio (2.392) among all regressors. CONCLUSIONS:GPC-1 expression significantly correlated with OS in patients with GBM who received radiotherapy and temozolomide treatment. GPC-1 expression can help predict the occurrence of dissemination and shorter OS in patients with GBM.
Authors: Galina M Kazanskaya; Alexandra Y Tsidulko; Alexander M Volkov; Roman S Kiselev; Anastasia V Suhovskih; Vyacheslav V Kobozev; Alexei S Gaytan; Svetlana V Aidagulova; Alexei L Krivoshapkin; Elvira V Grigorieva Journal: Histochem Cell Biol Date: 2018-01-10 Impact factor: 4.304
Authors: Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian Journal: Cochrane Database Syst Rev Date: 2021-03-12
Authors: Mei-Chun Yeh; Brian W C Tse; Nicholas L Fletcher; Zachary H Houston; Maria Lund; Marianna Volpert; Chelsea Stewart; Kamil A Sokolowski; Varinder Jeet; Kristofer J Thurecht; Douglas H Campbell; Bradley J Walsh; Colleen C Nelson; Pamela J Russell Journal: EJNMMI Res Date: 2020-05-07 Impact factor: 3.138
Authors: Dmitry M Polikarpov; Douglas H Campbell; Lucinda S McRobb; Jiehua Wu; Maria E Lund; Yanling Lu; Sergey M Deyev; Andrew S Davidson; Bradley J Walsh; Andrei V Zvyagin; David A Gillatt Journal: Cancers (Basel) Date: 2020-04-16 Impact factor: 6.639
Authors: Dhanusha Sabanathan; Douglas H Campbell; Vicki M Velonas; Sandra Wissmueller; Hubert Mazure; Marko Trifunovic; Pirooz Poursoltan; Kevin Ho Shon; Tiffany R Mackay; Maria E Lund; Yanling Lu; Paul J Roach; Dale L Bailey; Bradley J Walsh; David Gillatt; Howard Gurney Journal: Asia Ocean J Nucl Med Biol Date: 2021
Authors: Fatemah O F O Alshammari; Yousef M Al-Saraireh; Ahmed M M Youssef; Yahya M Al-Sarayra; Hamzeh Mohammad Alrawashdeh Journal: Onco Targets Ther Date: 2021-07-30 Impact factor: 4.147